2025
Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi
Wenger C, Asare E, Kwon J, Li X, Mwinjiwa E, Chinkhumba J, Jere K, Hungerford D, Cunliffe N, Paltiel A, Pitzer V. Cost-effectiveness analysis of alternative infant and neonatal rotavirus vaccination schedules in Malawi. PLOS Global Public Health 2025, 5: e0004341. PMID: 40209158, PMCID: PMC11984971, DOI: 10.1371/journal.pgph.0004341.Peer-Reviewed Original ResearchDose of RotarixNeonatal vaccinationThird doseDisability-adjusted life yearsRotavirus vaccination strategiesVaccination strategiesVaccination scheduleRV3-BB vaccineRotavirus vaccine scheduleModerate-to-severeCurrent rotavirus vaccinesProbabilistic sensitivity analysesRV3-BBPrevent rotavirusRotavirus casesRotavirus vaccineWTP thresholdAlternate infantsVaccine impactSevere diarrheaWeeks of ageRotarixVaccine effectivenessCost-effectiveness analysisCost-effective
2023
Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study
Phillips M, Antillon M, Bilcke J, Bar-Zeev N, Limani F, Debellut F, Pecenka C, Neuzil K, Gordon M, Thindwa D, Paltiel A, Yaesoubi R, Pitzer V. Cost-effectiveness analysis of typhoid conjugate vaccines in an outbreak setting: a modeling study. BMC Infectious Diseases 2023, 23: 143. PMID: 36890448, PMCID: PMC9993384, DOI: 10.1186/s12879-023-08105-2.Peer-Reviewed Original ResearchConceptsTyphoid Conjugate VaccineRoutine vaccinationReactive vaccinationVaccination strategiesOutbreak settingsMultidrug-resistant Salmonella typhiQueen Elizabeth Central HospitalTyphoid fever epidemicYears of ageMonths of ageCost-effectiveness analysisWorld Health OrganizationConjugate vaccineCentral HospitalRoutine immunizationVaccine deploymentPreventive vaccinationVaccinationTyphoid feverCost-effective strategyAge 15Health OrganizationFever epidemicAntimicrobial resistanceOutbreak definitions
2017
The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK
Meiring J, Gibani M, Group: T, Basnyat, Bentsi-Enchill A, Clemens J, Darton T, Date K, Dougan G, Garrett D, Gessner B, Gordon M, Heyderman R, Hombach J, Kotloff K, Levine M, Luby S, Mohan V, Marfin A, Mulholland K, Neuzil K, Pitzer V, Pollard A, Qadri F, Salisbury D, Zaidi A. The Typhoid Vaccine Acceleration Consortium (TyVAC): Vaccine effectiveness study designs: Accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a meeting held on 26–27 October 2016, Oxford, UK. Vaccine 2017, 35: 5081-5088. PMID: 28802757, DOI: 10.1016/j.vaccine.2017.08.001.Peer-Reviewed Original ResearchConceptsTyphoid Vaccine Acceleration ConsortiumEffectiveness study designStudy designImportant public health toolIntroduction of TCVsHigh disease burdenStrategic Advisory GroupPublic health toolGAVI-eligible countriesCost-effectiveness analysisIntroduction of typhoidEnteric feverPrevious vaccinesTyphoid vaccineDisease burdenEfficacious vaccineGlobal burdenCountry-level decisionsTyphoid epidemiologyTyphoid feverLatest evidenceVaccineTyphoid surveillanceEffectiveness studiesHealth tools
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply